Use of intrathecal trastuzumab in a patient with carcinomatous meningitis.
Laufman
L R
LR
Forsthoefel
K F
KF
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000473:pathology*; D002277:Carcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D002552:Cerebral Ventricles; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007276:Injections, Intraventricular; D007278:Injections, Spinal; D008279:Magnetic Resonance Imaging; D008577:Meningeal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D008581:Meningitis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D008875:Middle Aged; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab